Autopsy report · NCT02570711
Phase 2, Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Metastatic Pancreatic Cancer
Cause of deathFunding or business
“Sponsor Decision”
Life of this trial
- Ran for about 6 months before it stopped.
- 3 participants enrolled.
- Results were posted on the registry 3 years 4 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Acerta Pharma BV
- Sponsor type
- Industry
- Conditions
- Metastatic Pancreatic Cancer
- Interventions
- ACP-196; Nab-paclitaxel; Gemcitabine
- Participants
- 3
- Sites
- 10
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.